This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (32)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Radiologic Imaging  • PET/ SPECT Imaging  • Alert me on articles by topic  Social Bookmarking   What's this?

Levente Kerenyi, MD; George A. Ricaurte, MD, PhD; David J. Schretlen, PhD; Una McCann, MD; Jozsef Varga, PhD; William B. Mathews, PhD; Hayden T. Ravert, PhD; Robert F. Dannals, PhD; John Hilton, PhD; Dean F. Wong, MD, PhD; Zsolt Szabo, MD, PhD

Arch Neurol. 2003;60:1223-1229.

Background  Little is known about serotonin neurons in Parkinson disease (PD).

Objective  To study the serotonin system in PD with positron emission tomography, using the serotonin transporter radioligand [¹¹C](+)McN5652.

Design and Patients  We measured the density of the serotonin transporter and the density of [¹¹C]WIN35 428–labeled dopamine transporters in the striatum of 13 adults with PD and 13 age- and sex-matched controls. To assess the effects of possible differences in blood flow or brain atrophy, we also measured regional cerebral blood flow and the size of the regions of interest for the caudate nucleus and putamen.

Results  Patients with PD showed reductions in the specific distribution volumes of [¹¹C](+)McN5652 in the caudate (P<.01) and putamen (P<.01), along with the expected reductions in striatal [¹¹C]WIN35 428 binding (P<.01). There were no reductions in regional cerebral blood flow or the sizes of the regions of interest, mitigating against potential confounding effects of blood flow, brain atrophy, or partial volume effects. Reductions in serotonin transporter binding correlated with ratings of disease staging.

Conclusions  These results suggest that the density of serotonin transporters, like that of dopamine transporters, is reduced in the striatum of patients with PD and that these changes are related to disease stage.

From the Department of Neurology, Medical School Debrecen (Dr Kerenyi); Department of Nuclear Medicine, University of Debrecen (Dr Varga), Debrecen, Hungary; the Department of Radiology, Johns Hopkins Medical Institutions (Drs Ricaurte, Ravert, Dannals, Hilton, Wong, and Szabo), Baltimore Md; the Department of Psychiatry and Behavioral Sciences, School of Medicine (Dr Schretlen and McCann), and the Division of Nuclear Medicine (Dr Mathews), Johns Hopkins University, Baltimore.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serotonergic modulation of basal ganglia circuits: Complexity and therapeutic opportunities
Benarroch
Neurology 2009;73:880-886.
FULL TEXT  

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish et al.
Brain 2008;131:120-131.
ABSTRACT | FULL TEXT